Targeted Alpha-Therapy Market Outlook Highlights The Next Major Growth Opportunities
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Targeted Alpha-Therapy Market Forecast: What Market Value Is Expected By 2030?
The market for targeted alpha therapy has experienced swift expansion in recent years. Its value is projected to rise from $1.03 billion in 2025 to $1.2 billion in 2026, reflecting a compound annual growth rate (CAGR) of 17.2%. This historical period of growth has been driven by progress in nuclear medicine research, a growing number of unmet needs related to advanced cancers, the broadening of clinical trials involving radiopharmaceuticals, the availability of medical isotopes, and an increase in the uptake of targeted radiation therapy.
The market for targeted alpha therapies is projected to experience significant expansion in the coming years. By 2030, it is anticipated to reach a value of $2.25 billion, with a compound annual growth rate (CAGR) of 17.0%. During the forecast period, this growth will be driven by higher funding for isotope production facilities, a growing shift toward personalized radiation oncology, the application of targeted alpha therapies to new disease areas, increased regulatory backing for radiopharmaceuticals, and strengthened partnerships between nuclear medicine and oncology experts. Key trends shaping this future include the accelerated development of alpha-emitting radiopharmaceutical agents, a greater emphasis on targeted radioligand therapies, a stronger focus on precisely delivering radiation, improvements in isotope manufacturing infrastructure, and better integration of molecular targeting components.
Download A Free Sample Report For Comprehensive Market Insights:
Targeted Alpha-Therapy Market Growth Drivers: What Factors Are Accelerating Expansion?
The increasing emphasis on precision medicine is anticipated to accelerate the expansion of the targeted alpha-therapy market in the coming years. Precision medicine is a medical model that tailors prevention, diagnosis, and treatment to an individual’s genetic makeup, lifestyle, and environmental factors, aiming to achieve more effective health outcomes. Its adoption is rising due to the greater availability of genetic testing, which facilitates more accurate diagnoses and targeted therapies, leading to improved patient results. Targeted alpha-therapy supports precision medicine by directing highly potent alpha-emitting isotopes specifically to cancer cells, allowing for individualized and exact treatment while reducing harm to healthy tissues. For example, in March 2024, the American Pharmaceutical Review, a US-based journal, reported that global expenditure on precision medicine therapies was around $32 billion in 2022 and is expected to surpass $124 billion by 2027. Consequently, the heightened interest in precision medicine is fueling growth in the targeted alpha-therapy market.
Targeted Alpha-Therapy Market Segment Landscape And Growth Potential
The targeted alpha-therapy market covered in this report is segmented –
1) By Isotope Type: Actinium-225, Radium-223, Lead-212, Bismuth-213, Other Isotype Types
2) By Application: Prostate Cancer, Bone Metastases, Pancreatic Cancer, Other Applications
3) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Lymphoma, Other End Users
Subsegments:
1) By Actinium-225: Ac-225 Lintuzumab, Ac-225 PSMA-617, Ac-225 DOTATATE
2) By Radium-223: Radium-223 Dichloride (Xofigo)
3) By Lead-212: Pb-212 DOTAMTATE (AlphaMedix), Pb-212 TCMC-Trastuzumab
4) By Bismuth-213: Bi-213 Lintuzumab, Bi-213 DOTATOC
5) By Other Isotope Types: Thorium-227, Astatine-211, Terbium-149
Targeted Alpha-Therapy Market Trends: What Is Shaping Future Industry Growth?
Key players in the targeted alpha-therapy sector are concentrating on creating advanced solutions like peptide receptor radionuclide therapy to boost the effectiveness of cancer treatments, reduce unintended side effects, and improve patient results. Peptide receptor radionuclide therapy (PRRT) is a precision cancer approach where radioactive isotopes are delivered directly to tumor cells by attaching them to peptides that specifically bind to receptors found in high numbers on cancer cells, thus limiting harm to healthy tissues. For example, in February 2024, RadioMedix Inc., a biotechnology firm based in the US, collaborated with Orano Med, a US pharmaceutical company, and secured the first targeted alpha therapy to receive FDA breakthrough device designation—AlphaMedix (lead-212-Dotamtate)—designed for treating neuroendocrine tumors. This treatment targets advanced gastroenteropancreatic neuroendocrine tumors by delivering potent alpha radiation straight to malignant cells while preserving normal tissue. Its main benefit stems from the high energy and short range of alpha particles, which cause irreparable DNA damage in tumor cells with low toxicity. This therapy presents a hopeful choice for patients who are new to or have had insufficient responses to existing beta-emitter therapies, aiming to enhance both effectiveness and safety in challenging neuroendocrine tumor cases.
Targeted Alpha-Therapy Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the targeted alpha-therapy market are Bayer Aktiengesellschaft, Novartis AG, Lantheus Holdings Inc., Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen- und Medizintechnik AG, Actinium Pharmaceuticals Inc., RayzeBio Inc., ITM Isotope Technologies Munich SE, ARTBIO Inc., AdvanCell Pty Ltd., IONETIX Corporation, Abdera Therapeutics Inc., Aktis Oncology Inc., Alpha-9 Oncology Inc., Clarity Pharmaceuticals Pty Ltd., Nucleus RadioPharma, Oncoinvent AS, PanTera, Perspective Therapeutics Inc., RadioMedix Inc.
Access The Complete Targeted Alpha-Therapy Market Report:
Targeted Alpha-Therapy Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the targeted alpha-therapy market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the targeted alpha-therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
